Drug intelligence / Profile preview

EV-200

Development stage: Preclinical
Lead developer: Evrys Bio
Modality: Small Molecules

Overview

EV-200 is a preclinical-stage small molecule being developed by Evrys Bio for the treatment of chronic hepatitis B virus (HBV) infection. While the specific target for EV-200 is not explicitly detailed in current pipeline disclosures, it is developed within Evrys Bio's platform which focuses on sirtuin-2 (SIRT2) modulators. The company's approach involves targeting host cell proteins that are essential for viral replication, a strategy intended to provide broad-spectrum efficacy and a high barrier to the development of viral resistance. EV-200 represents a novel host-targeted therapeutic candidate aimed at achieving a functional cure for patients with chronic HBV.

Targets

SIRT2 (NAD-dependent protein deacetylase sirtuin-2)

Beyond the preview

Go deeper on EV-200.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EV-200.

Explore the full profile